Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc ...

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...

Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been ...

In today’s health-driven society, the pursuit of effective and natural solutions to improve well-being is at the forefront of ...

Herpesviruses, which cause skin and genital infections, neonatal diseases, and meningitis, can successfully persist over a ...

Late-Breaking scientific poster at the American Thoracic Society Advances in Pulmonary Vascular Disease sessions will present AV-001 activity in SARS-CoV-2 Infection/COVID-19 ...

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs.

The American Association for Cancer Research (AACR) will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick ...

NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...